Sanofi (EPA:SAN)
France
· Delayed Price · Currency is EUR | Market Cap | 112.15B |
| Revenue (ttm) | 44.29B |
| Net Income (ttm) | 5.56B |
| Shares Out | 1.22B |
| EPS (ttm) | 4.44 |
| PE Ratio | 20.87 |
| Forward PE | 11.11 |
| Dividend | 3.92 (4.27%) |
| Ex-Dividend Date | May 12, 2025 |
| Volume | 2,210,016 |
| Average Volume | 2,738,522 |
| Open | 91.25 |
| Previous Close | 91.88 |
| Day's Range | 90.01 - 91.91 |
| 52-Week Range | 85.07 - 110.88 |
| Beta | 0.48 |
| RSI | 34.77 |
| Earnings Date | Apr 24, 2025 |
About Sanofi
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. The company provides immunology and inflammation, rare diseases, neurology, oncology, and other medicines and vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines protecting against diphtheria, tetanus, pertussis, polio, Hib, and hepatitis B; inf... [Read more]
Financial Performance
In 2024, Sanofi's revenue was 44.29 billion, an increase of 7.73% compared to the previous year's 41.11 billion. Earnings were 5.56 billion, an increase of 2.96%.
Financial StatementsNews
Sanofi Asthma Drug Misses Primary Goal, Plans For Pivotal Study
Sanofi SA (NASDAQ: SNY) on Tuesday shared progress from its mid- to late-stage respiratory pipeline . The French drug maker reported preliminary results from the TIDE-Asthma phase 2 study of amliteli...
Sanofi flunks mid-stage trial for asthma drug
Press Release: Sanofi's respiratory pipeline advances with new data in asthma and plans for new clinical studies in COPD
Sanofi's respiratory pipeline advances with new data in asthma and plans for new clinical studies in COPD New phase 2 data for amlitelimab show efficacy in heterogeneous inflammatory asthma Lunsekimig...
Press Release: Sanofi's respiratory pipeline advances with new data in asthma and plans for new clinical studies in COPD
Sanofi's respiratory pipeline advances with new data in asthma and plans for new clinical studies in COPD New phase 2 data for amlitelimab show efficacy in heterogeneous inflammatory asthma Lunsekimig...
How Do Investors Really Feel About Sanofi?
Sanofi's (NYSE: SNY) short percent of float has fallen 30.77% since its last report. The company recently reported that it has 4.00 million shares sold short , which is 0.18% of all regular shares th...
Global pharma shares plunge as Trump doubles down on tariff threat
Global drugmakers' stocks dropped across the board after U.S. President Donald Trump reiterated plans for a "major" tariff on pharmaceutical imports, threatening an interwoven global supply chain, and...
Europe’s pharma titans confront von der Leyen with threat to yank $113 billion from EU and relocate to U.S. as Trump plans ’major’ tariffs
Novo Nordisk and Sanofi were among companies threatening to hasten their exits to the U.S., as Trump promised pharma tariffs were coming 'shortly.'
Trump teases targeted tariffs on overseas drug manufacturers
With the next set of White House–imposed tariffs just hours away from taking effect — including the attention-hogging 104% rate to be levied on products from China as they're imported into the U.S. — ...
Press Release: Tolebrutinib phase 3 data published in NEJM demonstrate benefit on disability progression in multiple sclerosis
Tolebrutinib phase 3 data published in NEJM demonstrate benefit on disability progression in multiple sclerosis Results from the HERCULES phase 3 study showed delay in disability progression in people...
Press Release: Tolebrutinib phase 3 data published in NEJM demonstrate benefit on disability progression in multiple sclerosis
Tolebrutinib phase 3 data published in NEJM demonstrate benefit on disability progression in multiple sclerosis Results from the HERCULES phase 3 study showed delay in disability progression in people...
Why Is French Pharma Giant Sanofi Stock Trading Higher On Thursday?
The U.S. Food and Drug Administration (FDA) on Thursday granted orphan drug designation to Sanofi SA‘s SNY rilzabrutinib.
Why Is French Pharma Giant Sanofi Stock Trading Higher On Thursday?
The U.S. Food and Drug Administration (FDA) on Thursday granted orphan drug designation to Sanofi SA ‘s (NASDAQ: SNY) rilzabrutinib. The treatment is an investigational, novel, advanced, oral, revers...
Lamb Weston Posts Better-Than-Expected Results, Joins Sanofi And Other Big Stocks Moving Higher On Thursday
U.S. stocks were lower, with the Dow Jones index falling over 1,200 points on Thursday. Shares of Lamb Weston Holdings, Inc . (NYSE: LW) rose sharply during Thursday's session after the company repor...
Press Release: Rilzabrutinib granted orphan drug designation in the US for two rare diseases with no approved medicines
Rilzabrutinib granted orphan drug designation in the US for two rare diseases with no approved medicines Designation granted for warm autoimmune hemolytic anemia and IgG4-related disease Rilzabrutinib...
Sanofi licensing deal boosts Nurix shares
Sanofi: Qfitlia Approval A Bright Spot As Landscape Darkens For European Pharma
Bernstein's Courtney Breen: Merck, Novo Nordisk, others at high risk from tariffs
Courtney Breen, Bernstein senior analyst, joins CNBC's 'Money Movers' to discuss how to draw the line between tariff risks and company financials in pharmaceuticals, which companies are most at risk, ...
Press Release: Qfitlia approved as the first therapy in the US to treat hemophilia A or B with or without inhibitors
Qfitlia approved as the first therapy in the US to treat hemophilia A or B with or without inhibitors Qfitlia (fitusiran), the first antithrombin-lowering therapy in hemophilia, offers consistent prot...
Sanofi gets FDA nod for its hemophilia treatment
US FDA approves Sanofi's bleeding disorder therapy
The U.S. Food and Drug Administration approved French drugmaker Sanofi's therapy, paving the way for a new type of treatment for patients 12 years of age and older with a rare disorder that prevents b...
AbbVie Vs. Sanofi: Which Is The Better Investment Right Now
Discover whether AbbVie or Sanofi holds the edge in the global immunology market and find out which stock shows more long-term promise.
Press Release: Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD
Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD Following recent approvals in the EU, China, and the US, this approval was based on pivotal phase 3 results in adu...
Sanofi’s chief digital officer says remote work means employees lose the ‘serendipity’ needed to innovate
"I think we were contrarians,” Sanofi's chief digital officer Emmanuel Frenehard told Fortune. “I think the contrarians are becoming the norm.”
Press Release: Chlamydia vaccine candidate granted fast track designation by the US FDA
Chlamydia vaccine candidate granted fast track designation by the US FDA Chlamydia infection can contribute to pelvic inflammatory diseases in women, which can lead to pregnancy complications or infer...